Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Meier

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 25, 2018
Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXTR A Bray, H M Gebel, R Townsend, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 29, 2011
The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantationS Busque, M Cantarovich, S Mulgaonkar, et al.
Kidney International|September 6, 2000
Effect of waiting time on renal transplant outcomeH U Meier-Kriesche, F K Port, A O Ojo, et al.
Transplantation Proceedings|March 27, 2001
Time to first graft loss as a risk factor for second renal allograft lossJ A Arndorfer, H U Meier-Kriesche, A O Ojo, et al.
Transplantation|August 10, 2000
Relationship of recipient age and development of chronic allograft failureH U Meier-Kriesche, A O Ojo, D M Cibrik, et al.
Transplantation|March 10, 2001
Interaction of mycophenolate mofetil and HLA matching on renal allograft survivalH U Meier-Kriesche, A O Ojo, A B Leichtman, et al.
Transplantation|March 10, 2001
Gender differences in the risk for chronic renal allograft failureH U Meier-Kriesche, A O Ojo, S F Leavey, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 28, 2016
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After TransplantS Florman, T Becker, B Bresnahan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 23, 2009
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trialR S Gaston, B Kaplan, T Shah, et al.
Transplantation|June 14, 2000
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistanceG S Friedman, D Wik, L Silva, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 25, 2018
Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXTR A Bray, H M Gebel, R Townsend, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 29, 2011
The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantationS Busque, M Cantarovich, S Mulgaonkar, et al.
Kidney International|September 6, 2000
Effect of waiting time on renal transplant outcomeH U Meier-Kriesche, F K Port, A O Ojo, et al.
Transplantation Proceedings|March 27, 2001
Time to first graft loss as a risk factor for second renal allograft lossJ A Arndorfer, H U Meier-Kriesche, A O Ojo, et al.
Transplantation|August 10, 2000
Relationship of recipient age and development of chronic allograft failureH U Meier-Kriesche, A O Ojo, D M Cibrik, et al.
Transplantation|March 10, 2001
Interaction of mycophenolate mofetil and HLA matching on renal allograft survivalH U Meier-Kriesche, A O Ojo, A B Leichtman, et al.
Transplantation|March 10, 2001
Gender differences in the risk for chronic renal allograft failureH U Meier-Kriesche, A O Ojo, S F Leavey, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 28, 2016
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After TransplantS Florman, T Becker, B Bresnahan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 23, 2009
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trialR S Gaston, B Kaplan, T Shah, et al.
Transplantation|June 14, 2000
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistanceG S Friedman, D Wik, L Silva, et al.
Pageof 23